A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Trial ID NCT00664898

PubWeight™ 3.66‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00664898

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013 1.16
2 Antibody-based therapies in multiple myeloma. Bone Marrow Res 2011 0.98
3 Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015 0.81
4 Target Therapy in Hematological Malignances: New Monoclonal Antibodies. Int Sch Res Notices 2014 0.76
Next 100